NanoViricides, Inc. Common Stock (NNVC)

NanoViricides, Inc. (NYSE American: NNVC) presented its latest advancements at the MicroCap Conference 2025 in Atlantic City on Jan. 29, highlighting its lead drug candidate, NV-387. The company is preparing for Phase II clinical trials of NV-387 for MPOX treatment in Africa, where the virus remains a public health concern. Designed to target a host-side feature used by most human pathogenic viruses, NV-387 has demonstrated broad-spectrum antiviral activity in animal models, including against MPOX, influenza, RSV, and coronaviruses. NanoViricides emphasized NV-387’s superior efficacy compared to existing antiviral treatments like Tamiflu and Xofluza, positioning it as a potential breakthrough in infectious disease management. The company also highlighted its proprietary drug delivery platform, which could expand treatment options for non-oral drugs. With an estimated market potential exceeding $10 billion, NanoViricides is seeking investment and licensing opportunities to accelerate NV-387’s development.

SHELTON, CT / ACCESS Newswire / January 29, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it is presenting today, January 29, at 11am at the MicroCap Conference 2025 in Atlantic City, NJ.

NanoViricides, Inc. (NYSE American: NNVC) announced it has engaged a Clinical Research Organization (“CRO”) to conduct a Phase II clinical trial for its broad-spectrum antiviral drug, NV-387. The host-mimetic drug, which mimics cellular attachment receptors to block viral infections, has demonstrated strong antiviral activity in preclinical models against orthopoxviruses, including MPox and Smallpox, and outperformed existing antiviral treatments in other infection models. The trial will evaluate NV-387’s efficacy against MPox, a disease caused by the human Mpox virus (“hMPXV”), which currently has no effective treatments. CEO Dr. Anil R. Diwan emphasized the drug’s potential to revolutionize antiviral therapy, positioning NV-387 as a critical solution for combating viral

SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum antiviral drug NV-387 further into the regulatory pipeline.

SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are going around already.

Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs designed to resist viral escape, announced it will present at the Biotech Showcase 2025 on Jan. 14 in San Francisco. Anil R. Diwan, PhD, the company’s president and executive chairman, will provide updates on NanoViricides’ pipeline, including NV-387, a Phase II-ready drug with potential applications against a wide range of viral infections such as influenza, RSV, MPox, smallpox, and COVID-19. NV-387 is engineered to target host-side features essential for viral infections, offering potential advantages over current treatments. The company will also showcase its platform for oral delivery of non-oral drugs, which could meet significant market demand. The market potential for NV-387’s indications exceeds $10 billion. Biotech Showcase runs parallel to the JP Morgan Life Sciences Conference, offering a key networking venue for therapeutic development executives and investors.

SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference.

NanoViricides, Inc. (NYSE American: NNVC) announced significant progress on NV-387, a broad-spectrum antiviral demonstrating superior efficacy in animal models against rapidly mutating RNA viruses, including H5N1 bird flu, RSV, hMPV, and lethal coronaviruses. As viruses like H5N1 evolve to evade vaccines and existing drugs, NV-387’s mechanism, mimicking host cell features required for infection, minimizes resistance risk. Amid rising cases of severe respiratory viruses and the first U.S. fatality from H5N1 this month, the company emphasized the urgent need for robust, broad-spectrum treatments, positioning NV-387 for clinical trials in 2025 to address unmet medical needs.

NanoViricides, Inc. (NYSE American: NNVC) has highlighted its broad-spectrum antiviral drug candidate, NV-387, as a crucial tool to combat a potential H5N1 bird flu pandemic. According to Anil R. Diwan, Ph.D., President and Executive Chairman of the company, NV-387 targets essential host-side features that the rapidly evolving H5N1 virus relies on, making it less likely for the virus to develop resistance. This stands in contrast to existing antiviral treatments, which are becoming less effective as the virus mutates. While the U.S. government has stockpiled H5N1 vaccines, current plans do not include their deployment, and NanoViricides emphasizes that vaccines may struggle to keep up with the virus’s rapid evolution. The company asserts that NV-387’s ultra-broad antiviral spectrum, effective against various viruses including Influenza, RSV, and COVID-19, positions it as a powerful preventative measure against a potential pandemic.

SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug.

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a key gathering for microcap and small-cap investors, offering a platform for investment and collaboration.

NanoViricides, Inc. (NYSE American: NNVC), has filed its Quarterly Report for the period ending Sept. 30, 2024, detailing $3.87 million in cash and cash equivalents, $7.36 million in net property and equipment assets, and $1.63 million in current liabilities. The company utilized $2.6 million in operating activities during the quarter, including $1 million for R&D ahead of planned Phase II clinical trials for NV-387, targeting MPOX infection in Central Africa and RSV in the U.S. Additional funding of $0.63 million from an At-the-Market offering and a $3 million line of credit bolsters NanoViricides’ operational capabilities, though the company notes that current resources are insufficient to sustain operations through November 2025.

SHELTON, CT / ACCESSWIRE / November 15, 2024 / SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057824001991/nnvc-20240930x10q.htm).

NanoViricides (NYSE American: NNVC) will present a corporate update at the Spartan Capital Investors Conference today, Nov. 4, 2024, at 9:45 a.m. ET, detailing its lead antiviral drug candidate, NV-387, which is Phase 2-ready and targets a broad range of viral infections. Dr. Anil R. Diwan, the company’s President and Executive Chairman, highlighted NV-387’s successful Phase 1 results and its superior efficacy in animal models against viruses such as RSV, Influenza, COVID, and Smallpox. Leveraging NanoViricides’ innovative technology platform, NV-387 aims to address an estimated market exceeding $10 billion by 2027, with RSV treatment alone valued at $2.5 to $4.3 billion.

SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be presenting a corporate update at the Spartan Capital Investors Conference on Monday, November 4, 2024 (today) at 9:45 am. The Conference will be held at the Pierre Hotel in New York City.

NanoViricides (NYSE American: NNVC) announced that its President and Executive Chairman, Dr. Anil R. Diwan, will present at the PODD Conference on Oct. 28, 2024, highlighting the company’s innovative nanomedicine platform and its antiviral drug candidate NV-387. Dr. Diwan will discuss the platform’s ability to revolutionize drug delivery by enhancing bioavailability and protecting drugs from metabolism. He will also showcase NV-387’s promising results in treating respiratory viruses and its superior performance in animal models against treatments like oseltamivir and remdesivir.

SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be presenting a talk at the PODD Conference on Monday, October 28th, 2024 at 345pm. The PODD Conference will be held at the Westin Boston Seaport District, MA on October 28 and 29, 2024.

NanoViricides (NYSE American: NNVC), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, is in the spotlight in the most recent episode of the PODD podcast. The company announced that president and executive chair Anil R. Diwan, PhD, was interviewed during the Oct. 11 episode of the program, which was released on PharmaTalkRadio. During the interview, Diwan discussed the company’s proprietary nanoviricides technology platform as well as its potentially revolutionary broad-spectrum antiviral clinical drug candidate, NV-387. According to the announcement, based on animal model studies, NV-387 exhibits potential to completely revolutionize the treatment of viral infections, much like penicillin changed the treatment of bacterial infections decades ago.

SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, was interviewed in a podcast by the PODD Conference* host. The podcast was published on October 11, 2024, on PharmaTalkRadio.

NanoViricides (NYSE American: NNVC) is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. NanoViricides’ President and Executive Chairman Anil R. Diwan, Ph.D., is expected to present at the Global AMR Summit, the premier forum for anti-microbial resistance (“AMR”), to be held at the Kimpton Marlowe Hotel in Cambridge, MA, on October 9, 2024. Dr. Diwan will discuss the company’s “shape-shifting,” “Trojan Horse” platform technology, which facilitates the delivery of one or more “war-heads” against a pathogen to combat AMR. The technology delivers these “war-heads” directly onto the pathogen without affecting normal host cells, thus reducing toxicity and improving pharmacokinetics.

NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2024, on September 27, 2024. The company reported cash and cash equivalents of $4.97 million, approximately $7.5 million in Net Property and Equipment (“P&E”) assets (after depreciation), and total current liabilities of approximately $1.36 million as of June 30, 2024. During fiscal 2024, the company utilized net cash of approximately $6.31 million for operating activities, including certain expenditures for Phase 1a/1b clinical trial of NV-387 and drug manufacturing costs for this clinical trial.

SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2024 with the Securities and Exchange Commission (SEC) on Friday, September 27, 2024. The report can be accessed at the SEC website (https://www.sec.gov/ix?doc=/Archives/edgar/data/1379006/000141057824001650/nnvc-20240630x10k.htm).

NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, today announced that it has executed a broad Memorandum of Understanding (“MoU”) agreement with TheraCour Pharma Inc., an R&D firm, signed on September 23, 2024. As a result, the company has now obtained a right of first refusal (“ROFR”) for all antiviral drug developments from TheraCour. According to the announcement, the MoU encompasses all antiviral drug developments and is a crucial step that provides NanoViricides with certain intellectual property rights for developing treatments against any viral infections.

SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal (ROFR) for all antiviral drug developments from the R&D firm TheraCour Pharma, Inc. ("TheraCour").